Alvogen, Inc.
Alvogen, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 2009, the company has rapidly expanded its operations across key regions, including North America, Europe, and Asia. Alvogen focuses on developing and manufacturing generic and specialty pharmaceuticals, with a strong emphasis on high-quality, affordable medications. The company is recognised for its innovative approach to drug development, particularly in the areas of oncology, respiratory, and central nervous system therapies. Alvogen's commitment to quality and efficiency has positioned it as a competitive force in the market, achieving significant milestones such as the successful launch of numerous generic products. With a robust portfolio and a dedication to improving patient access to essential medicines, Alvogen continues to make strides in the pharmaceutical landscape.
DitchCarbon Score
How does Alvogen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alvogen, Inc.'s score of 29 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alvogen, Inc.'s reported carbon emissions
In 2022, Alvogen, Inc. reported total carbon emissions of approximately 721,000 kg CO2e across all scopes. This included 19,000 kg CO2e from Scope 1 emissions, primarily from direct operations, and 217,000 kg CO2e from Scope 2 emissions, mainly from purchased electricity. The most significant contribution came from Scope 3 emissions, which totalled about 721,000 kg CO2e, with business travel accounting for 573,000 kg CO2e. In 2021, Alvogen's emissions were approximately 294,000 kg CO2e in Scope 3, with a total of 12,000 kg CO2e from Scope 1 and 206,000 kg CO2e from Scope 2. The company saw a slight increase in Scope 2 emissions in 2022 compared to 2021, while Scope 1 emissions increased from 12,000 kg CO2e in 2021 to 19,000 kg CO2e in 2022. Despite these figures, Alvogen has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction targets suggests that while the company is aware of its emissions, it may not yet have formalised commitments to reduce them in line with industry standards or frameworks such as the Science Based Targets initiative (SBTi). Overall, Alvogen's emissions data highlights the need for enhanced climate commitments and strategies to effectively manage and reduce their carbon emissions moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 16,000 | 00,000 | 00,000 |
| Scope 2 | 202,000 | 000,000 | 000,000 |
| Scope 3 | 261,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alvogen, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
